证券代码：300482 证券简称：万孚生物 公告编号：2025-039 债券代码：123064 债券简称：万孚转债 广州万孚生物技术股份有限公司 第五届监事会第十次会议决议公告 本公司及监事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 广州万孚生物技术股份有限公司（以下简称"公司"）第五届监事会第十次会议 于 2025 年 8 月 19 日下午 14:00 在公司会议室以现场与通讯相结合方式召开，会议 通知于 2025 年 8 月 10 日以邮件、电话的方式向全体监事发出。会议应到监事 3 名， 实到 3 名，会议召开符合《公司法》和《公司章程》规定。会议由公司监事彭雷清 女士主持。 经与会监事认真审议，本次会议审议并通过以下议案： 一、审议通过《关于<2025 年半年度报告及其摘要>的议案》 经核查，监事会认为：董事会编制和审核 2025 年半年度报告的程序符合法律、 行政法规以及中国证监会的有关规定，报告内容真实、准确、完整地反映了 公司 经营、管理及财务等各方面的实际情况，不存在任何虚假记载、误导性陈述或者重 大遗漏。 三、审议通过《关于公司及控股子公司 2025 ...

华泰联合证券有限责任公司关于 广州万孚生物技术股份有限公司全资子公司终止与关联企 业共同投资暨关联交易的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐机构"）作 为广州万孚生物技术股份有限公司（以下简称"万孚生物"或"公司"）2022 年度 创业板向特定对象发行股票的保荐机构，根据《证券发行上市保荐业务管理办 法》、《深圳证券交易所创业板股票上市规则》、《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等有关规定，对万孚生物全资 子公司终止与关联企业共同投资暨关联交易情况进行了核查，具体情况如下： 广州万孚生物技术股份有限公司（以下简称"公司"）于 2022 年 4 月 24 日 召开第四届董事会第十次会议，第四届监事会第七次会议审议通过了《关于全 资子公司与关联企业共同投资暨关联交易的议案》，同意公司的全资子公司海南 万信产业发展有限公司（下称"海南万信"）拟与公司的关联方海南众美企业管 理有限公司（下称"海南众美"）共同投资设立海南安汇科技有限公司。项目总 投资额预计 22,500 万元，其中海南万信拟出资 6,750 万元、出资比例为 30%， 海南众美拟 ...

Core Insights - Yun Tai Yuan Biological Technology (Yunnan) Co., Ltd. has been established with a registered capital of 1 million RMB and is represented by Wu Lianghong [1] Business Scope - The company is involved in various licensed projects including feed production, food production, food internet sales, beverage production, tea product production, halal food production, and grain processing food production [1] - General projects include the production, sales, processing, transportation, and storage of agricultural products, as well as sales of agricultural by-products, initial processing of edible agricultural products, supply chain management services, wholesale of edible agricultural products, and seafood [1] - The company also engages in the wholesale and acquisition of seafood, sales of pre-packaged health foods, import and export of food, and internet sales of pre-packaged food [1]

Summary of Key Points Core Viewpoint - The Hong Kong biotechnology sector experienced a significant decline, with most stocks falling sharply, indicating a bearish trend in the market [1]. Company Performance - **Gilead Sciences (歌礼制药-B)**: Decreased by 15.06%, latest price at 15.510, market cap at 14.946 billion [2]. - **Yunkang Group (云康集团)**: Fell by 14.18%, latest price at 2.300, market cap at 1.429 billion [2]. - **PAG Pharmaceuticals (派格生物医药-B)**: Dropped by 9.15%, latest price at 31.760, market cap at 12.258 billion [2]. - **Tengsheng Boao (腾盛博药-B)**: Declined by 8.30%, latest price at 2.210, market cap at 1.590 billion [2]. - **China Antibody (中国抗体-B)**: Decreased by 7.49%, latest price at 3.210, market cap at 4.371 billion [2]. - **Jiahua Biotech (嘉和生物-B)**: Fell by 7.08%, latest price at 4.460, market cap at 2.347 billion [2]. - **Sillod Pharmaceuticals (思路迪医药股份)**: Dropped by 6.06%, latest price at 7.910, market cap at 2.042 billion [2]. - **Tiger Med (泰格医药)**: Decreased by 5.73%, latest price at 54.250, market cap at 46.711 billion [2]. - **Kangji Medical (加科思-B)**: Fell by 5.69%, latest price at 8.120, market cap at 6.404 billion [2]. - **WuXi AppTec (药明巨诺-B)**: Dropped by 5.14%, latest price at 5.720, market cap at 2.382 billion [2]. - **Three Leaf Clover Biotech (三叶草生物-B)**: Decreased by 5.13%, latest price at 0.740, market cap at 0.960 billion [2]. - **Yiming Oncology (宜明昂科-B)**: Fell by 4.76%, latest price at 12.810, market cap at 5.218 billion [2]. - **Junshi Biosciences (君实生物)**: Decreased by 4.69%, latest price at 34.540, market cap at 35.462 billion [2]. - **Zhonghui Biotech (中慧生物-B)**: Fell by 4.39%, latest price at 51.150, market cap at 20.125 billion [2]. - **Zhaoyan New Drug (昭衍新药)**: Decreased by 4.38%, latest price at 23.140, market cap at 17.343 billion [2].

天眼查App显示，近日，合肥晨晖生物科技有限公司成立，法定代表人为吴承路，注册资本100万人民 币，经营范围为一般项目：技术服务、技术开发、技术咨询、技术交流、技术转让、技术推广；仪器仪 表制造；电子元器件制造；实验分析仪器销售；办公用品销售；教学用模型及教具销售；教学专用仪器 销售；仪器仪表销售；专用化学产品制造（不含危险化学品）；专用化学产品销售（不含危险化学 品）；化工产品销售（不含许可类化工产品）；医学研究和试验发展；消毒剂销售（不含危险化学 品）；电子产品销售；五金产品批发；五金产品零售；塑料制品销售；橡胶制品销售；技术玻璃制品销 售；第一类医疗器械销售；第二类医疗器械销售；模具销售；建筑材料销售；电线、电缆经营；机械电 气设备销售；金属材料销售；日用百货销售；劳动保护用品销售；互联网销售（除销售需要许可的商 品）；软件开发；信息咨询服务（不含许可类信息咨询服务）；企业管理咨询；市场营销策划；市场调 查（不含涉外调查）；会议及展览服务；技术进出口；国内贸易代理（除许可业务外，可自主依法经营 法律法规非禁止或限制的项目）许可项目：检验检测服务（依法须经批准的项目，经相关部门批准后方 可开展经营活动，具 ...

研究还发现了一个引人注目的现象：当培养温度从常规的37℃降至34℃（接近睾丸生理温度）时， 无论是源自男性还是女性iPSC的细胞，进入减数分裂的效率均显著提高。这一结果挑战了低温仅有利 于精子生成的传统认知，为未来构建人工卵巢微环境提供了重要线索。 此次团队另辟蹊径，完全绕过PGC阶段，直接激活减数分裂程序。他们通过基因工程改造干细胞， 使其一旦启动减数分裂便发出荧光信号，便于实时监测。随后，他们又系统筛选了多种基因组合，并结 合两种小分子化合物，显著提升了减数分裂的诱导效率。 经过对超过64万个细胞的高通量测试，团队鉴定出3个关键调控基因：BOLL、MEIOC和HOXB5。 令人意外的是，HOXB5此前并未被明确关联到减数分裂过程里，而此次发现揭示了其潜在的重要作 用。 实验结果显示，在优化条件下，细胞可在约12天内完成减数分裂的前两个阶段——细线期和偶线 期。到第15天，部分细胞进入粗线期，实现遗传物质交换。这是人类细胞在体外首次被明确诱导进入这 一核心生殖过程。 科技日报北京8月18日电 （记者张梦然）一项由美国哈佛大学Wyss研究所与哈佛医学院联合开展的 突破性研究，首次在体外引导人类诱导多能干细胞（ ...

Core Insights - The report highlights a strong recovery in the core business of King’s Ray Bio, with a significant increase in revenue and adjusted net profit for 1H25, leading to an upward revision of guidance for the life sciences segment [1][2] - The closing price of King’s Ray Bio is HKD 18.17, with a target price set at HKD 28.75, indicating a potential upside of 58.2% [1] Financial Performance - For 1H25, the company reported a revenue increase of 82% year-on-year to USD 519 million, and an adjusted net profit growth of 510% to USD 178 million [1] - The life sciences segment saw an 11% revenue growth with an adjusted gross margin of 51.0%, and the full-year revenue growth guidance for this segment has been raised to 13-15% [1] - The custom services revenue in the booming bio segment returned to double-digit growth, with 20 new antibody protein drug projects and 30 CGT projects acquired in 1H25 [1] Business Segments - The report details the performance of various business segments: - **Life Sciences**: Revenue growth of 11%, with a full-year growth guidance of 13-15% and a stable gross margin expected [1] - **Booming Bio**: Custom services revenue growth guidance maintained at 15-20%, with expectations for the first non-COVID BLA project in 2H25 [1] - **Baisjie**: Revenue growth of 8% with an adjusted gross margin of 40.4%, focusing on team building and early strain screening [1] Valuation and Ratings - The report maintains a "Buy" rating for King’s Ray Bio, with a slight upward adjustment of revenue forecasts for 2025-2027 by 1-5%, while lowering the net profit forecast for 2025 due to significant net losses [2] - The SOTP (Sum of the Parts) valuation model has been rolled over to 2026, with target valuation multiples for each business segment remaining unchanged [2]

Company Overview - Shanghai Yingduobao Biotechnology Co., Ltd. has been recently established with a registered capital of 500,000 RMB [1] - The legal representative of the company is Chen Fengbo [1] Business Scope - The company operates in various sectors including technology services, development, consulting, and transfer [1] - It is involved in the processing of soil and fertilizers, sales of fertilizers, and research and development of biological organic fertilizers and compound microbial fertilizers [1] - Additional services include agricultural horticulture, pest control for crops, and forestry pest control [1] - The company also engages in smart agricultural management, agricultural scientific research, and testing development [1] - It provides ordinary goods warehousing services, chemical product sales, and specialized chemical product sales [1] - The company is authorized to produce fertilizers, subject to approval from relevant authorities [1]

证券代码：688575 证券简称：亚辉龙 公告编号：2025-045 深圳市亚辉龙生物科技股份有限公司 控股股东、实际控制人兼董事长及部分高管兼核心 技术人员减持股份计划公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： ? 股东持股的基本情况 截至本公告披露日，深圳市亚辉龙生物科技股份有限公司（以下简称"亚辉 龙"或"公司"）控股股东、实际控制人兼董事长胡鹍辉先生持有公司股份 发行股票前持有的股份及因权益分派转增的股份，均已上市流通；公司副总经理 兼核心技术人员肖育劲先生持有公司股份 2,480,000 股，占公司股份总数的比例 为 0.4348%，上述股份为公司首次公开发行股票前持有的股份、因权益分派转增 的股份及第二类限制性股票激励归属获得的股份，均已上市流通。 ? 减持计划的主要内容 因个人资金需求，胡鹍辉先生计划通过集中竞价、大宗交易方式减持其持有 的公司股份，合计数量不超过 17,112,804 股，占公司股份比例不超过 3%。减持 期间为自本公告披露之日起 15 个交易日后的 3 ...

Group 1 - The "Youth Startup Internship Program 2025" organized by Cyberport and the Hong Kong SAR Government's Home Affairs and Youth Affairs Bureau has successfully concluded, providing 100 internship positions and attracting over 4,300 applications [1] - Cyberport's CEO, Mr. Zheng Songyan, emphasized the organization's commitment to nurturing the next generation of technology talent to help Hong Kong achieve its vision of becoming an international innovation and technology hub [1] - Since its launch in 2021, the program has received over 20,300 applications and provided 400 internship positions, becoming a significant initiative for cultivating technology talent in Hong Kong [1] Group 2 - This year's program received applications from 168 Cyberport companies, with more than half participating for the first time [1] - The selected 100 internship positions cover a wide range of fields, including data analysis, fintech, biotechnology, AI applications, business development, marketing, and design [1] - During the internship period, 18 interns will visit leading companies in the Greater Bay Area, such as Baidu, Meituan, and EHang, to gain insights into the thriving development of tech enterprises in the region and interact with young entrepreneurs [1]